Breaking Historic Steam Tugboat Emerges from Sava River Amidst Severe Drought Prince Harry Highlights Need for Better Veteran Transition to Civilian Careers Prince Harry and Meghan to Visit UK Amid Royal Family Reconciliation Hopes Emails Reveal U.S. Immigration Collaboration with Iran on Deportations Amidst Conflict Champagne Harvest Accelerates Amidst Extreme Heat and Drought
Thursday August 20, 2026
81° Honolulu, HI Mostly Clear
Become a Contributor
Section

Partners

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
Press Release

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced positive topline results from the Phase 3 INTerpath-001…

Business Wire · 9 minutes ago
Read Full Story